Earnings Call · Q2 FY2022·2022-08-04

Q2 22EPS -3.28%·Rev n/aQ1 22EPS +7.94%·Rev n/aQ4 21EPS -12.50%·Rev n/aQ3 21EPS -3.77%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations

Fred Vogt — Interim President and Chief Executive Officer

Igor Bilinsky — Chief Operating Officer

Jim Ziegler — Executive Vice President, Commercial

Friedrich Finckenstein — Chief Medical Officer

Jean-Marc Bellemin — Chief Financial Officer

−2.9%1d on move date−2.7% vs SPY3d−4.2%5d−5.6%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access